Roche Holding AG

ROG

CH0012032048

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,605

Sector

Pharmaceuticals

Calendar

2024-09-16 - Pharma Day

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

ROCHE HOLDING : Strong Q2 led to a guidance upgrade

July 25, 2024 at 12:00 pm EDT

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

265.60CHF

Average target price

297.08CHF

Spread / Average Target

+11.85%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Swiss Exchange Other stock markets 11:31:14 2024-09-13 am EDT			5-day change	1st Jan Change
265.60 ^CHF	+0.99%		-3.14%	+8.63%

Sep. 13	FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System	MT
Sep. 13	Roche Gets FDA Approval for Multiple-Sclerosis Treatment	DJ

FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System	Sep. 13	MT
Roche Gets FDA Approval for Multiple-Sclerosis Treatment	Sep. 13	DJ
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis	Sep. 13	CI
Swiss Market Index Joins Regional Rally in Europe	Sep. 13	MT
Transcript : Roche Holding AG - Shareholder/Analyst Call	Sep. 13
A central bank and it's off again?	Sep. 13
ROCHE : Bank of America raises its recommendation to 'buy	Sep. 13	CF
Deutsche Bank Downgrades Roche to Sell, Cuts PT	Sep. 13	MT
ROCHE : Deutsche Bank downgrades its recommendation to 'sell	Sep. 13	CF
ROCHE HOLDINGS AG : Deutsche Bank lowers its rating to Sell	Sep. 13	ZD
Halozyme Therapeutics Says FDA Approves Tecentriq Hybreza Cancer Immunotherapy	Sep. 13	MT
Roche: FDA approves Tecentriq Hybreza	Sep. 13	CF
Roche Obtains US FDA Approval for Tecentriq Hybreza Subcutaneous Cancer Immunotherapy	Sep. 13	MT
FDA Approves Roche?s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy	Sep. 13	CI
Genentech Receives FDA Approval for Cancer Treatment	Sep. 12	DJ
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Tecentriq Hybreza? With ENHANZE® for Multiple Types of Cancer	Sep. 12	CI
Roche: collaboration agreement with Qritive in AI	Sep. 12	CF
ECB to cut rates without lowering its guard	Sep. 12
Roche Shares Slump on Oral Weight-Loss Drug Candidate Side Effects -- Update	Sep. 12	DJ
Roche Shares Slump on Oral Weight-Loss Drug Candidate Side Effects	Sep. 12	DJ
Roche shares drop on side effects result in early-stage obesity pill trial	Sep. 12	RE
European shares jump 1% on tech boost; ECB meet in focus	Sep. 12	RE
ROCHE HOLDINGS AG : Receives a Sell rating from Goldman Sachs	Sep. 12	ZD
The mood is getting heavier, but Taylor Swift is keeping watch	Sep. 11
Weight-loss market to see 16 new drugs by 2029, report estimates	Sep. 10	RE

Roche Holding AG

Equities

ROG